Vaccine Facts: Immunocompromised People Should Get a Third Dose

Immunocompromised people have a reduced ability to fight infections and are more vulnerable to severe COVID-19. That is why the U.S. Centers for Disease Control and Prevention (CDC) is recommending that people with moderately to severely compromised immune systems receive an additional dose of the Pfizer-BioNTech or Moderna vaccine.

In this Q&A, Meenakshi Rana, MD, Associate Professor of Medicine (Infectious Diseases) at the Icahn School of Medicine at Mount Sinai, and the Director of Transplant Infectious Disease, explains why immunocompromised people, who make up almost three percent of the U.S. population, should get this third vaccine dose and why it is important to take other protective measures.

New Guidance on COVID-19 Vaccines: In April 2023, the Food and Drug Administration and the Centers for Disease Control and Prevention announced some major changes for COVID-19 vaccines. Click here to read more about what you need to know.

What did the CDC recommend?

The CDC and the Advisory Committee on Immunization Practices took an important action to prevent COVID-19 infection in our immunocompromised population and among transplant recipients. They now recommend that people who are moderately to severely immunocompromised receive an additional dose of an mRNA COVID-19 vaccine, either Pfizer or Moderna, at least 28 days after the completion of the initial series. The Food and Drug Administration (FDA) now allows for the additional dose for these people as well.

To be clear, this is not considered a booster dose. A booster dose is given to a patient whose immunity to the vaccine may have waned over time. This is considered an additional dose, given to immunocompromised patients to improve their initial response to the vaccine series. These patients are essentially receiving a three-dose mRNA vaccine series instead of a two-dose series.

Who is considered immunocompromised and should get the third dose?

Meenakshi Rana, MD

Immunocompromised patients are a very large and heterogeneous group. For the purposes of an additional COVID-19 vaccine, the CDC has defined a specific moderately to severely immunocompromised group, which includes:

  • Patients who have been receiving active cancer treatment for tumors or cancers of the blood
  • Patients who had a solid organ transplant, such as a heart, lung, liver or a kidney, and currently take immunosuppressive medications
  • Patients who had a bone marrow transplant within two years or had a bone marrow transplant and are currently taking immunosuppressive therapy, or patients who receive CAR T-cell therapy.
  • Patients who have advanced or untreated HIV
  • Patients who have another medical condition that require high-dose steroids or immunosuppressive therapy for that medical condition

If you think you fall within this category, it’s important that you speak to your physician to determine if you are eligible for an additional dose of mRNA COVID-19 vaccine.

Why is the CDC taking this action?

Patients who are considered moderately to severely immunocompromised are more vulnerable to COVID-19. They are more likely to have severe disease, and more likely to be hospitalized with COVID-19. In addition, there has been data suggesting that moderately to severely immunocompromised patients may not have as strong an immune response to the initial COVID-19 vaccine series, and we have seen breakthrough infections in vaccinated immunocompromised patients, occasionally requiring hospitalization. The CDC also now has data suggesting that a third vaccine would be safe.

What should I do if I think I am affected by this action by the CDC?

If you think you are considered moderately to severely immunocompromised, talk to your doctor to see if you are eligible for an additional dose of COVID-19 vaccine. The CDC recommends that you receive a third dose with the same mRNA vaccine. For example, if you received an initial Moderna vaccine series, then you should complete your series with an additional third dose of the Moderna vaccine.

What if I am immunocompromised and I received the Johnson & Johnson vaccine?

When the CDC made this recommendation, they did not have enough data on whether immunocompromised patients who received the J&J vaccine would have an improved response after receiving an additional dose of the same vaccine. For this reason, we are currently awaiting more guidance from the CDC on what to recommend for these patients.

If I am immunocompromised, what else should I do to protect myself?

In addition to receiving an additional dose of an mRNA vaccine, you should continue to practice all those protective precautions that we’ve been discussing: social distancing, hand hygiene, and masking. It’s also very important that all of those around you, your family and your friends, are all vaccinated.

The FDA has also authorized the use of a medication, known as a monoclonal antibody, for what is termed “post- exposure prophylaxis.” That means, if you are exposed to a loved one or family member with COVID-19, this medication can be given to you to prevent COVID-19 and progression to severe disease or hospitalization with COVID-19. You should call your physician to see if you are eligible.

Should I get an antibody test to see if I am eligible for the third dose?

We are not recommending that you get an antibody test for this purpose, because we don’t know what level of antibodies is considered protective. We recommend that if you are considered immunocompromised, you should receive an additional vaccine dose, regardless of antibody response.

Twenty Years Later: A Grim Anniversary as Mount Sinai Remains a Lifeline for 9/11 Responders

On the evening of Tuesday, September 11, 2001—with fires burning at the site of where the twin towers had stood that morning and several thousand people still unaccounted for—a group of physicians from the Mount Sinai Selikoff Centers for Occupational Health met to discuss a plan of action for treating survivors and first responders who had rushed in to help.

Protégés of the late Irving Selikoff, MD—a pioneering researcher who was the first to definitively link asbestos exposure to lung cancer—these physicians knew how dangerous the air was at the site of the attack, which had been reduced to 1.8 million tons of burning rubble. The toxic stew of chemicals would later be found to include major hazards to human health, such as lead and other heavy metals, benzene, dioxin, and asbestos. The physicians also knew that serious illnesses could develop decades after an individual’s initial exposure, lessons they had learned from Dr. Selikoff and his groundbreaking research in the 1960s.

Over the course of their first meeting and several subsequent ones that included colleagues such as David Prezant, MD, Chief Medical Officer of the Fire Department of the City of New York (FDNY), the Mount Sinai physicians established a blueprint for what is now the World Trade Center (WTC) Health Program.

Today, 20 years later, the WTC program continues to receive new patients. It consists of six New York City-area medical centers, including Mount Sinai, and a separate treatment center exclusively for FDNY members. Together, the centers treat more than 80,000 emergency responders—firefighters, police, recovery and cleanup workers—as well as 30,000 people who worked, lived, or went to school near the disaster zone in lower Manhattan. Their medical care will be funded through 2090, under the federal James Zadrogra 9/11 Health and Compensation Act, which was signed into law in 2011.

“The Selikoff Centers had exceptional doctors and they worked their fingers to the bone getting this program off the ground,” says Michael Crane, MD, MPH, who joined Mount Sinai in 2006 as Director of the World Trade Center Health Program Clinical Center at Mount Sinai. “Their incredible dedication got this going. It was hardscrabble, making phone calls and asking people to speak out about the program. They were helped by community and civic leaders and members of Congress who got behind this. Their story is really an inspiration.”

Dr. Crane, whose program at Mount Sinai cares for roughly 23,000 responders, was medical director of Con Edison’s health program on 9/11. Immediately following the attacks, he was down at the site making sure Con Edison’s recovery workers had proper masks and breathing protection. But that was not the case for many other responders. The filters on their masks clogged up after an hour and workers were either too busy to replace them or could not find extra masks.

Sandra Lowe, MD, talks about what we’ve learned about trauma and resilience from treating responders. Her answers have implications for COVID-19 and beyond. Dr. Lowe is Medical Director at the World Trade Center Mental Health Program Clinical Center of Excellence at Mount Sinai.

 

“You’d see the masks hanging off their faces,” says Dr. Crane. “They were running in to save people’s lives. They ran in without appropriate equipment and suffered the consequences.”

The dedication of the recovery workers was inspiring, says Dr. Crane. “So many of them had friends or relatives or people they knew or had trained with down there. Guys who ran down there had built the towers. So it was a tremendous emotional shock. They were energized by this passion to do something about it. So many of them said the same thing: ‘It’s family. I want to find them.’ It was deep and personal and real.”

Michael Crane, MD, MPH, left, and Julia Nicolaou Burns, Administrative Director, Selikoff Centers for Occupational Health

On 9/11, Craig L. Katz, MD, was the newly appointed Director of The Mount Sinai Hospital’s Psychiatry Emergency Room. But it was his leadership of the nonprofit organization, Disaster Psychiatry Outreach, which he had founded during his medical residency, which led to his direct involvement with the families of the victims, survivors, and responders. Almost immediately, Dr. Katz helped organize volunteer psychiatrists who met informally with these groups down at Ground Zero or at the Family Assistance Center that New York City had established downtown.

At the time, lung screenings for responders were being funded by the National Institute for Occupational Safety and Health (NIOSH), but no federal funding had been allocated for mental health. Yet the psychological effects of the troubling rescue and recovery mission were beginning to show.

A few months after the attacks, Dr. Katz says Mount Sinai’s Psychiatry Department received a phone call from the late Stephen Levin, MD, then Medical Director of the Mount Sinai Selikoff Centers for Occupational Health, who said, “ ‘I have all these rescue and recovery workers coming into my office and they’re crying. I don’t know what to do with them. I’m looking at lung exposures and they’re crying.’”

Craig L. Katz, MD

Looking to assist the workers, Dr. Katz, currently a Clinical Professor in the departments of Psychiatry, Medical Education, and System Design and Global Health, at the Icahn School of Medicine at Mount Sinai, wrote a three-page grant proposal to the private Robin Hood Foundation requesting funding for mental health. “That was the birth of the mental health program for recovery workers,” he says.

The Robin Hood Foundation would go on to provide the program with more than $6 million until 2011, when the Zadroga Bill was enacted, according to Dr. Katz. “Robin Hood typically funds underserved populations,” he says. “They agreed the rescue and recovery workers were an underserved population. They were largely men who don’t readily seek help for mental health issues. These blue collar guys were not our usual customers.”

Today, Mount Sinai’s World Trade Center (WTC) Mental Health Program actively treats close to 700 individuals under the leadership of Sandra M. Lowe, MD, Medical Director. “The people involved in the recovery and restoration operations were exposed to so much trauma,” says Dr. Lowe. “Some individuals developed post-traumatic stress disorder (PTSD), major depressive disorder, all kinds of anxiety disorders, and some developed substance misuse problems because that was one of the ways they tried to manage the symptoms they had.”

These mental health conditions, combined with the aero-digestive disorders, lymphoma, or lung cancer, which also stem from their work at Ground Zero, have created a complicated set of issues for this aging cohort of responders, many of whom are now in their 50s.

Sandra M. Lowe, MD

“Some members of the public may question the relevance of the WTC Health Center 20 years later,” says Dr. Lowe. “It is very relevant and needed. People are not aware of the ongoing physical or psychological struggles. We see an increased number of patients coming in for help. They have developed worsening physical conditions or now they’re retiring from the New York City Police Department. They may have been suffering PTSD for 20 years, but now they’re no longer afraid of the stigma associated with seeking help. They’ll say, ‘Doc, this is the first time I’ve told anyone about my nightmares.’ We hear the appreciation from the patients and their families.”

As time goes on, Mount Sinai’s clinical team also sees new health issues arising among responders, including the possibility of early cognitive decline. NIOSH is funding studies to determine whether exposure to toxins at Ground Zero is actually associated with this decline and whether there is a need for an early intervention program.

Kathryn Marrone, LCSW, Director of Social Work for the World Trade Center Mental Health Program, joined Mount Sinai in the summer of 2002 for what she was told at the time would be a one-year job monitoring and assessing the needs of responders. Almost two decades later, she is still working with these men and women. Only now, she says, they are aging and require a shift in services.

The responders “recovered bodies, saw people jumping from buildings, and watched the buildings collapse,” she says. “The level of trauma these individuals experienced was quite severe. They were completely confused about how to manage that emotionally.” But over the years, in their dealings with social workers, doctors, and other colleagues in the program, “Mount Sinai has become a lifeline for so many individuals. It is a place where they can turn because no one else quite gets what they’re experiencing.”

Mount Sinai Brings ‘Vaxmobile’ to Community Event in Harlem

Staff from Mount Sinai Morningside, from left: Ruby Guzman, Maytal Rand, and Amy Bush

Mount Sinai Morningside, in collaboration with Mount Sinai South Nassau, participated in Harlem Week’s “A Great Day in Harlem” event on Sunday, August 8, at the Ulysses S. Grant National Memorial.

In partnership with One Hundred Black Men, Mount Sinai premiered a series of videos featuring members of the community and local celebrities encouraging people to protect themselves and their loved ones against COVID-19 by getting vaccinated.

“Thanks to Mount Sinai South Nassau’s vaccination mobile unit—the Vaxmobile—and the incredible staff from Mount Sinai Morningside, we were able to engage residents of Harlem in conversations about the vaccine, and we even provided the vaccine onsite to those ready to roll up their sleeves,” said Amy Bush, Director, Volunteer Services, Mount Sinai Morningside. “In line with the mission of the event, we were honored to have the opportunity to educate attendees, and also give hope to Harlem by spreading immunity in the community.”

Mount Sinai Offers Challenge Coins to Recognize Staff Pandemic Efforts

In July, Mount Sinai Health System’s leadership offered staff the opportunity to receive a Commemorative COVID-19 Challenge Coin to recognize their selfless dedication and commitment during the height of the COVID-19 pandemic in 2020 and 2021.

Challenge Coins, as they have become known, are an important tradition, particularly within the crisis-response community, symbolizing a catastrophic event and recognizing the teamwork and individual sacrifice needed to overcome such events. In the past, they have been given to front-line workers after historical events of importance, such as 9/11 and Hurricane Maria relief efforts in Puerto Rico.

Click here to see three Mount Sinai employees reflecting on challenge coins they received for crisis responses.

In that tradition, this coin is designed to recognize the teamwork and partnership that characterized Mount Sinai’s response to the COVID-19 pandemic. Inscribed on one side of the coin are those exact two words. The opposing side bears a representation of how Mount Sinai’s eight hospitals (marked by eight stars) and hundreds of ambulatory sites—bolstered by clinical, ambulatory, administrative, and operations staff, trainees, and students—united as a system that, together in service, gave and continues to give everything to those who need us most.

Many sites across Mount Sinai hosted events or had managers make rounds to distribute the coins with letters of gratitude. Many other sites are still distributing the coins.

“We offer this small but meaningful token of our deep appreciation. We hope that it will serve as one way to memorialize the remarkable efforts you have made as individuals and as members of a team that met and countered this disastrous pandemic” says Kenneth L. Davis, MD, President and Chief Executive Officer of Mount Sinai Health System.

Making Sense of the Pandemic Now

If you are fully vaccinated, are you protected from COVID-19? Will we need booster shots? What is the best way to keep children safe as they return to school?

These and other pressing questions were discussed in an Aspen Ideas Festival virtual event, in which Kenneth Davis, MD, MD, President and Chief Executive Officer of the Mount Sinai Health System, interviewed Judith A. Aberg, Dean of System Operations for Clinical Sciences, and Chief of the Division of Infectious Diseases, and Harm van Bakel, PhD, Assistant Professor of Genetics and Genomic Sciences and a leader of Mount Sinai’s Pathogen Surveillance Program. The interview, which was released in July, can be viewed here.

Dr. Aberg, who leads Mount Sinai’s COVID-19 clinical trial efforts, shared a favorite analogy about the vaccines’ effectiveness: “An umbrella will keep you dry for the most part, but you can still get wet in a bad storm,” she said. In the same fashion, “the current vaccines are highly effective even for the circulating variants, but we do expect there will be breakthrough infections in some individuals. So I encourage everyone to get vaccinated.”

How Mount Sinai is Transforming Care for Patients with Brain, Spine, and Central Nervous System Disorders

Mount Sinai’s departments of Neurology and Neurosurgery are committed to innovation for the treatment of disorders of the brain, spine, and central nervous system. That commitment has been recognized now that The Mount Sinai Hospital’s Neurology and Neurosurgery departments were ranked for the first time among the top 10 in the nation by U.S. News & World Report.

Joshua B. Bederson, MD

For decades, the departments have expanded clinical and research programs offering ground-breaking treatments for patients with a wide range of conditions, including cancer, brain tumors, and strokes as well as neurological disorders such as Parkinson’s disease, epilepsy, and multiple sclerosis, and psychiatric disorders such as major depression.

“Over the years, this process has involved recruiting the best and brightest neurosurgeons who align with my vision of highly specialized care, centers of excellence, and programs within each subspecialty that are as deep and as broad as an entire neurosurgery department,” says Joshua B. Bederson, MD, Leonard I. Malis, MD / Corinne and Joseph Graber Professor of Neurosurgery and System Chair, Department of Neurosurgery. “It’s also been meaningful to collaborate with the Department of Neurology to support their own recruits and create joint programs that provide comprehensive, well-rounded care to patients with neurological conditions.”

Added Barbara G. Vickrey, MD, MPH, System Chair, Department of Neurology, and Henry P. and Georgette Goldschmidt Professor of Neurology: “Our ranking is an acknowledgement of the Neurology Department’s leadership in clinical care on a national basis. We excel in treating the most challenging neurological patients and providing high-quality care to all of our New York City communities, including those that are under-resourced.”

In this Q&A, Dr. Bederson and Dr. Vickrey discuss how changes they have made over the years have helped patients.

What are some of the most significant changes the Department of Neurosurgery has made?

Over the past several years, our focus has been on building our divisions that deal with different disease states such as brain tumors, vascular problems and stroke, pediatric neurosurgery, movement disorders, and epilepsy. We recruited the nation’s best and brightest leaders in each one of these areas, building programs around their expertise into very strong, and sometimes very large divisions, many of which rival the average neurosurgery department in other parts of this country.

What are some national and global accomplishments?

Some of our national and global accomplishments focus on the creation of the division sub-specializations. In the cerebrovascular space, we recruited one of the world’s great leaders, Dr. J Mocco, to direct our Cerebrovascular Center, and he’s turned it into a very large service line with 10 full-time faculty. We are making groundbreaking changes to clinical treatment, including reducing the “time to needle” and treatment from the onset of stroke down to very low numbers, meaning very fast treatment times. We are achieving results that are the best in the world.

We’ve created centers of excellence around movement disorders, with one of the great deep brain stimulation programs and neurostimulation for intractable epilepsy. We have one of the largest pituitary tumor, skull base surgery, and malignant brain tumor programs in the country, with numerous NIH-funded research studies, and a large number of novel clinical trials in each of these areas. Our Division of Neurocritical Care is a large, world-class division with a unique Neuro Emergencies Management and Transfers (NEMAT) program transferring more than 1,000 patients with critical neurological illness every year.

How does the Department of Neurosurgery advance industry and academia?

Neurosurgery is inherently a technological field, and we rely very heavily on advanced digital and other technologies in the operating room. Through a significant partnership with industry, we have innovated in many creative ways, including in the use of augmented and virtual reality and the use of artificial intelligence that support our advanced digital platforms. We’ve created a new division called Sinai BioDesign, which is an incubator for innovative device creation. Here, surgeons work together with bioengineers to create new solutions for fixing problems that we face in the operating room and turn those solutions into products and companies.

How do these accomplishments result in better outcomes for neurosurgical patients?

All of our activities are aimed at improving patient outcomes. By creating centers of excellence, we can take advantage of our large health system by concentrating normally rare diseases into high volume centers, giving surgeons and other health care professionals the experience they need to become experts. They leverage the high volume to develop clinical protocols and research protocols that allow us to advance care in each disease state. Sinai BioDesign is creating new solutions and devices to help us treat conditions that require new solutions through advanced technologies, improving safety for patients.

Barbara G. Vickrey, MD, MPH

What changes has the Department of Neurology made?

The Neurology Department has grown dramatically in education, research, and clinical care in the last five years. Our department has had an approximately two-and-a-half-fold increase in NIH funding over five years. We have recruited more than 70 new faculty, who have been recruited both internally from our talented Mount Sinai graduates and from major academic institutions around the United States.

What are some specific areas of success?

We strive to improve outcomes in multiple sclerosis, Parkinson’s disease, stroke, epilepsy, headache, neuropathies, brain and spinal cord tumors, dementia, and other neurological disorders in children and adults, and we have subspecialty fellowship training programs in all these areas.  We have well-regarded centers, programs, and divisions that are dedicated to this mission, such as the Corinne Goldsmith Dickinson Center for Multiple Sclerosis, which is known for providing the best available multiple sclerosis care, including access to a wide range of clinical trials and a wellness program.

How does this make a difference for patients?

The Department provides patients with a unique blend of personalized and coordinated care, groundbreaking research, and technology. This integrated approach is instrumental in our pursuit of improving outcomes.

Can you give some examples?

Patients who come to our Comprehensive Stroke Center experience better outcomes on average than those of other New York City hospitals and other comprehensive stroke centers. Our Epilepsy Program provides a spectrum of treatments from the latest medications to vagal nerve stimulation and coordinates with Neurosurgery when surgical intervention is needed, with the goal of living seizure-free. Our patients in any subspecialty can count on physicians who have experience with unusual disorders as well as more common ones. In short, patients can expect to experience the benefits of a large, academic medical center along with personalized care. It’s the best of both worlds.